Oryzon Genomics S.A. (ORYZF)
USD 3.03
(-0.66%)
USD 3.03
(-0.66%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.35 Million EUR | 20.76% |
| 2022 | -4.23 Million EUR | 9.72% |
| 2021 | -4.68 Million EUR | -37.87% |
| 2020 | -3.39 Million EUR | 7.74% |
| 2019 | -3.68 Million EUR | -213.06% |
| 2018 | -1.17 Million EUR | 77.35% |
| 2017 | -5.19 Million EUR | 4.61% |
| 2016 | -5.44 Million EUR | -449.27% |
| 2015 | -991.9 Thousand EUR | -114.91% |
| 2014 | 6.65 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.23 Million USD | 38.02% |
| 2024 Q2 | 107.17 Thousand EUR | 110.04% |
| 2024 Q3 | -1.37 Million EUR | -1386.72% |
| 2023 Q3 | -1.06 Million EUR | -200.14% |
| 2023 Q2 | 1.06 Million EUR | 165.12% |
| 2023 Q1 | -1.62 Million EUR | 29.68% |
| 2023 FY | -3.35 Million EUR | 20.76% |
| 2023 Q4 | -1.72 Million EUR | -62.14% |
| 2022 Q1 | -1.8 Million EUR | 13.46% |
| 2022 Q2 | 325.07 Thousand EUR | 117.99% |
| 2022 FY | -4.23 Million EUR | 9.72% |
| 2022 Q3 | -628.75 Thousand USD | -293.42% |
| 2022 Q4 | -2.31 Million EUR | -268.45% |
| 2021 Q2 | 800.92 Thousand EUR | 144.02% |
| 2021 FY | -4.68 Million EUR | -37.87% |
| 2021 Q3 | -1.58 Million USD | -297.63% |
| 2021 Q1 | -1.81 Million EUR | -60.5% |
| 2021 Q4 | -2.08 Million USD | -31.89% |
| 2020 Q2 | -198.56 Thousand EUR | 82.79% |
| 2020 FY | -3.39 Million EUR | 7.74% |
| 2020 Q4 | -1.13 Million EUR | -24.11% |
| 2020 Q3 | -913.43 Thousand EUR | -360.02% |
| 2020 Q1 | -1.15 Million EUR | -21.83% |
| 2019 Q2 | -548.35 Thousand EUR | 54.57% |
| 2019 Q1 | -1.2 Million EUR | -60.03% |
| 2019 Q4 | -947.17 Thousand EUR | 3.56% |
| 2019 FY | -3.68 Million EUR | -213.06% |
| 2019 Q3 | -982.17 Thousand EUR | -79.11% |
| 2018 FY | -1.17 Million EUR | 77.35% |
| 2018 Q2 | 1.58 Million EUR | 254.43% |
| 2018 Q3 | -980.24 Thousand EUR | -161.97% |
| 2018 Q4 | -754.3 Thousand EUR | 23.05% |
| 2018 Q1 | -1.02 Million EUR | 21.32% |
| 2017 Q4 | -1.3 Million EUR | -11.66% |
| 2017 Q2 | -1.44 Million EUR | -11.83% |
| 2017 Q1 | -1.28 Million EUR | 0.37% |
| 2017 FY | -5.19 Million EUR | 4.61% |
| 2017 Q3 | -1.16 Million EUR | 19.08% |
| 2016 Q2 | -2.07 Million EUR | -186.2% |
| 2016 FY | -5.44 Million EUR | -449.27% |
| 2016 Q1 | -724.15 Thousand EUR | -14.68% |
| 2016 Q4 | -1.29 Million EUR | 4.79% |
| 2016 Q3 | -1.35 Million EUR | 34.46% |
| 2015 Q3 | -384.64 Thousand EUR | -150.46% |
| 2015 Q4 | -631.47 Thousand EUR | -64.17% |
| 2015 FY | -991.9 Thousand EUR | -114.91% |
| 2015 Q1 | -738.09 Thousand EUR | 0.0% |
| 2015 Q2 | 762.31 Thousand EUR | 203.28% |
| 2014 FY | 6.65 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | 21.66% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.527% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1126.378% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.781% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -15.923% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 106.329% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.148% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -84.174% |
| Marizyme, Inc. | -65.34 Million USD | 94.869% |
| Genus plc | 7.9 Million USD | 142.442% |
| Pharming Group N.V. | -10.54 Million USD | 68.213% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -54.527% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 9.63% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 62.088% |
| ContraFect Corporation | -65.15 Million USD | 94.854% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -94.097% |
| IMV Inc. | -36.48 Million USD | 90.81% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 58.399% |
| ONE Bio Corp. | 8.67 Million USD | 138.643% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.514% |
| Mesoblast Limited | -87.95 Million USD | 96.188% |
| MultiCell Technologies, Inc. | -380.07 USD | -882090.912% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 10.181% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.488% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -430.188% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -40.828% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 49.013% |
| Biomind Labs Inc. | -1.21 Million USD | -176.117% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -8.098% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 57.574% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.093% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -72.012% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 69.216% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -22288.775% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 31.377% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 51.983% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 78.874% |
| Accustem Sciences Inc. | -3.74 Million USD | 10.503% |
| EV Biologics, Inc. | -1.26 Million USD | -164.608% |
| Q BioMed Inc. | -2.05 Million USD | -63.391% |
| GB Sciences, Inc. | -1.36 Million USD | -146.236% |
| Alpha Cognition Inc. | -13.77 Million USD | 75.655% |
| CSL Limited | 2.64 Billion USD | 100.127% |
| Agentix Corp. | -1.37 Million USD | -143.99% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.386% |
| Enzolytics Inc. | -2.17 Million USD | -54.029% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | 7.121% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -5.723% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 42.362% |
| argenx SE | -295.05 Million USD | 98.864% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.644% |
| HST Global, Inc. | -146.21 Thousand USD | -2193.238% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3521.37% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -91.076% |
| Halberd Corporation | -79.67 Thousand USD | -4108.222% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 148.421% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -10.8% |
| Zenith Capital Corp. | -10.59 Million USD | 68.357% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 15.607% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 19.127% |
| AVAX Technologies, Inc. | -6.41 Million USD | 47.722% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5447.5% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -67.219% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -14326.224% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 29.696% |
| Helix BioMedix, Inc. | -1.05 Million USD | -217.496% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 12.204% |
| Kadimastem Ltd | -3.3 Million USD | -1.377% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 60.474% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -659.669% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -151.076% |
| LadRx Corporation | 400.44 Thousand USD | 937.308% |
| Cell Source, Inc. | -5.32 Million USD | 36.989% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -707.007% |
| Regen BioPharma, Inc. | 1.02 Million USD | 427.593% |
| Regen BioPharma, Inc. | 1.02 Million USD | 427.593% |
| Affymax, Inc. | -14.42 Million USD | 76.754% |
| Mobile Lads Corp. | -2.26 Million USD | -48.145% |
| Itoco Inc. | -1.86 Million USD | -79.398% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 24.526% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -100.895% |
| International Stem Cell Corporation | -131 Thousand USD | -2459.498% |
| CytoDyn Inc. | -49.84 Million USD | 93.273% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4142.459% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1369.77% |
| Qrons Inc. | -789.34 Thousand USD | -324.774% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -256.117% |
| SYBLEU INC | -180.3 Thousand USD | -1759.605% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -60.606% |
| Rebus Holdings, Inc. | -1.02 Million USD | -228.72% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -107.904% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6078.035% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -32.514% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.025% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -58.607% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -329.376% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -5.838% |
| Neutra Corp. | -233.46 Thousand USD | -1336.165% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 83.476% |
| PureTech Health plc | -65.69 Million USD | 94.896% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 84.234% |
| IXICO plc | -1.17 Million USD | -184.63% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 66.224% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.131% |
| CSL Limited | 2.64 Billion USD | 100.127% |
| Cellectis S.A. | -103.17 Million USD | 96.75% |